Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer (AEGEAN)
Source: View publication →
In patients with resectable non-small-cell lung cancer, perioperative treatment consisting of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy significantly improved pathological complete response and event-free survival compared to neoadjuvant chemotherapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The AEGEAN trial demonstrated that incorporating durvalumab both before and after surgery provides a clinically meaningful and statistically significant improvement in event-free survival and pathological complete response for patients with resectable early-stage NSCLC. This established a highly effective multi-modal treatment strategy that avoids excess surgical delays or toxicity, culminating in the FDA approval of the regimen in August 2024 for adults with resectable (tumors ≥ 4 cm and/or node positive) NSCLC with no known EGFR/ALK mutations.
Historical Context
Historically, surgical resection followed by adjuvant platinum-doublet chemotherapy was the standard of care for early-stage NSCLC, though 5-year survival rates remained suboptimal due to high rates of distant relapse. Following the success of immune checkpoint inhibitors in advanced disease, trials like CheckMate 816 validated neoadjuvant chemoimmunotherapy, while trials like IMpower010 and KEYNOTE-091 established the role of adjuvant immunotherapy. The phase 3 AEGEAN trial emerged alongside trials like KEYNOTE-671 to assess a comprehensive, continuous 'perioperative' approach—utilizing immunotherapy both in the neoadjuvant setting with chemotherapy and in the adjuvant setting as monotherapy. This reflects a modern paradigm shift toward intensifying systemic therapy in the curative-intent early-stage lung cancer setting.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of durvalumab complement traditional cytotoxic chemotherapy in the neoadjuvant setting for NSCLC?
Key Response
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and releasing the inhibition of T-cell mediated immune responses. Cytotoxic chemotherapy causes tumor cell death and antigen release, which primes T-cells. Administering durvalumab when the tumor bulk and intact draining lymphatics are present maximizes the systemic immune response against these exposed neoantigens, a foundational concept in tumor immunology.
When evaluating a patient with newly diagnosed stage IIIA NSCLC, what clinical parameters and potential surgical complications must you consider before recommending a perioperative chemoimmunotherapy regimen like the one used in the AEGEAN trial?
Key Response
Residents must balance the benefit of improved pathological complete response against the risk of immune-related adverse events and surgical delays. Neoadjuvant immunotherapy can cause pneumonitis or severe inflammatory reactions that may complicate surgery (e.g., dense hilar fibrosis) or delay curative-intent resection. Assessment of PD-L1 status, EGFR/ALK mutations, and baseline pulmonary function is crucial.
The AEGEAN trial demonstrated improvements in both pCR and EFS. How do we interpret the discordance that sometimes occurs between pCR and long-term EFS in individual patients, and what biomarkers are currently being investigated to better predict which patients actually need the adjuvant durvalumab phase?
Key Response
While pCR is a strong surrogate for survival at the trial level, individual patients achieving pCR might still relapse, and those without pCR might be cured. Furthermore, giving 1 year of adjuvant durvalumab to a patient with a pCR might be overtreatment. Clearance of circulating tumor DNA (ctDNA) representing minimal residual disease is a critical biomarker currently being evaluated to guide escalation or de-escalation of adjuvant therapy.
With multiple recent trials showing benefit for neoadjuvant or perioperative immunotherapy in resectable NSCLC, how do you decide between a purely neoadjuvant approach versus a perioperative approach in your clinical practice?
Key Response
Attendings must navigate overlapping data without direct head-to-head comparisons. CheckMate 816 showed benefit with only neoadjuvant therapy, while AEGEAN adds up to a year of adjuvant durvalumab. The decision involves weighing the financial toxicity and potential for chronic immune-related adverse events of a year of immunotherapy against potential EFS benefits, often factoring in final surgical pathology and patient tolerance.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The AEGEAN trial utilized a dual primary endpoint of pCR and EFS. What are the statistical implications of using a surrogate endpoint alongside a clinical endpoint in a phase 3 trial, and how does missing data or informative censoring in the adjuvant phase complicate the EFS analysis?
Key Response
Alpha-spending strategies must strictly control type I error when dual endpoints are used. Furthermore, patients dropping out before the adjuvant phase due to toxicity or surgical complications introduces informative censoring. If not appropriately modeled using techniques like inverse probability weighting or competing risk analysis, this can severely bias Kaplan-Meier EFS estimates.
As an editor evaluating the AEGEAN manuscript, how would you scrutinize the contribution of the adjuvant durvalumab phase given that the control arm received placebo after surgery?
Key Response
A major methodological limitation of perioperative trial designs is the lack of a neoadjuvant-only control arm. The control arm gets neoadjuvant chemo, surgery, then placebo. The experimental gets neoadjuvant chemo plus IO, surgery, then IO. If EFS is improved, it is statistically impossible to isolate whether the adjuvant IO was necessary or if the neoadjuvant IO drove the entire benefit. Editors should demand explicit discussion of this confounding factor.
Based on the AEGEAN trial, should current guidelines be updated to mandate a perioperative approach over a purely neoadjuvant approach for resectable NSCLC, and what level of evidence supports the use of adjuvant IO in patients who achieve a pCR?
Key Response
Current NCCN guidelines include both neoadjuvant and perioperative IO combinations as Category 1 or 2A recommendations. The committee must grapple with the lack of comparative effectiveness research. Recommending against adjuvant IO in pCR patients lacks prospective validation, yet giving it incurs toxicity. Guidelines must carefully reflect the absence of trial designs that isolate the adjuvant phase benefit, keeping both options open rather than mandating the longer perioperative course.
Clinical Landscape
Noteworthy Related Trials
IMpower010
Tested
Adjuvant atezolizumab following resection and chemotherapy
Population
Patients with completely resected stage IB-IIIA NSCLC
Comparator
Best supportive care
Endpoint
Disease-free survival (DFS)
CheckMate 816
Tested
Neoadjuvant nivolumab plus platinum-based chemotherapy
Population
Patients with resectable stage IB to IIIA NSCLC
Comparator
Platinum-based chemotherapy alone
Endpoint
Event-free survival (EFS) and pathological complete response (pCR)
KEYNOTE-671
Tested
Perioperative pembrolizumab (neoadjuvant with chemo plus adjuvant)
Population
Patients with resectable stage II to IIIB NSCLC
Comparator
Neoadjuvant chemotherapy plus placebo
Endpoint
Event-free survival (EFS) and overall survival (OS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis